| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT01005914 Details | 2023-01-06 Interventional | 2 | 11 | Asparaginase Cyclophosphamid… Cytarabine Dexamethasone Doxorubicin Imatinib Mesyla… Liposomal doxor… Methotrexate Methylprednisol… Methylprednisol… Methylprednisol… Pegaspargase Vincristine Leukemia Leukemia, Lymph… Precursor Cell … | Increased rate of bacterial infections Study terminated early due to safety concerns. Only one subject completed the study. | |||
| NCT05014919 2010-020493-42 Details | 2023-01-05 Interventional | 3 | 35 | Vortioxetine Depression Depressive Diso… | The study was terminated based on new efficacy data from another study. The study was terminated based on new efficacy data from another study. The main primary and secondary efficacy objectives were not assessed due to termination of the study and the limited number of participants who completed the double-blind period. | |||
| NCT04786964 Details | 2023-01-05 Interventional | 3 | 25 | Carboplatin Dexamethasone Folic Acid Pemetrexed Vitamin B 12 Carcinoma, Non-… Lung Neoplasms Metastatic Non-… | Regional political conflict - | |||
| NCT03355170 Details | 2023-01-05 Interventional | 4 | 0 | Dexlansoprazole Domperidone Lansoprazole Cardiovascular … Cardiac Event GERD Safety Issues | The sponsor decided to continue with a different design and a different protocol. - | |||
| NCT01339910 Details | 2023-01-04 Interventional | 3 | [1 Refs] | 272 | Busulfan Cyclophosphamid… Fludarabine Fludarabine pho… Melphalan Vidarabine Leukemia Leukemia, Myelo… Leukemia, Myelo… Myelodysplastic… Preleukemia Leukemia, Myelo… | Accrual terminated as recommended by the data and safety monitoring board. - | ||
| NCT03484520 2017-003213-26 Details | 2022-12-30 Interventional | 1 | 48 | Venetoclax Leukemia Leukemia, Myelo… Leukemia, Myelo… Cancer - Acute … | Strategic considerations - | |||
| NCT00849667 2008-005872-29 Details | 2022-12-30 Interventional | 3 | 1100 | Carboplatin Farletuzumab Taxane Carcinoma, Ovar… Hypersensitivit… Ovarian Neoplas… Ovarian Cancer | Lack of efficacy Study termination was based on the primary analysis results for progression-free survival (PFS). Data collection and analyses of health care resource utilization were not performed due to the study being terminated early. Pharmacokinetic data was collected and analyzed for a maximum of only 7 participants in this study. | |||
| NCT02923531 Details | 2022-12-29 Interventional | 1/2 | 9 | Nivolumab Carcinoma Carcinoma, Rena… Clear Cell Rena… | Due to low enrollment, the study was terminated early. Due to low enrollment, the study was terminated early. Data for some pre-registered endpoints were therefore not collected or analysed and could not be reported. | |||
| NCT05205447 Details | 2022-12-28 Interventional | 1 | 27 | Carbamazepine Itraconazole Healthy | Data from part 2 no longer deemed necessary for this program. - | |||
| NCT03662711 Details | 2022-12-28 Interventional | 4 | 843 | Bronchodilator … Olodaterol Lung Diseases Lung Diseases, … Pulmonary Disea… | Contract terminated between AIFA and the Sponsor (University of Ferrara) - | |||
| NCT02871297 2008-005356-25 Details | 2022-12-28 Interventional | 3 | 662 | Vortioxetine Depression Depressive Diso… Depressive Diso… | The study was terminated based on new efficacy data from another study. The study was terminated early based on new efficacy data from another study. | |||
| NCT02097121 2014-000464-17 Details | 2022-12-28 Interventional | 3 | 56 | Botulinum Toxin… Botulinum Toxin… abobotulinumtox… Enuresis Urinary Bladder… Urinary Inconti… Overactive Urinary Bladder | - - | |||
| NCT02038634 Details | 2022-12-28 Interventional | 4 | 16 | Betamethasone Tenosynovitis DeQuervain's Te… | not enough patient data Early termination due to lack of subject participation; statistical analysis not done due to small numbers. Outcome Measure # 2 was originally posted but was deleted as it was not included as part of the study design. No data was collected for that proposed outcome. | |||
| NCT01022138 Details | 2022-12-23 Interventional | 2 | 43 | Cyclophosphamid… Breast Neoplasm… Breast Cancer | - - | |||
| NCT04515394 2020-001776-15 Details | 2022-12-22 Interventional | 2 | 3 | Cetuximab Tepotinib Colorectal Neop… | The study was terminated early due to operational challenges identifying suitable participants
for screening in the study. - | |||
| NCT03711318 Details | 2022-12-22 Interventional | 3 | 8 | Buprenorphine Buprenorphine, … Naloxone Heroin Dependen… | continuing study was no longer feasible - | |||
| NCT03704298 Details | 2022-12-22 Interventional | 1 | 15 | Axicabtagene ci… Cyclophosphamid… Fludarabine Lymphoma Lymphoma, B-Cel… Relapsed/Refrac… | Development program terminated - | |||
| NCT05484167 Details | 2022-12-21 Interventional | 4 | 0 | Methyltestoster… Testosterone Testosterone 17… Testosterone en… Testosterone un… Erectile Dysfun… Sexual Dysfunct… | They study lost funding and decided to close the study down. - | |||
| NCT05387577 Details | 2022-12-21 Interventional | 1 | 6 | Estradiol Estradiol 17 be… Estradiol 3-ben… Polyestradiol p… Blood Coagulati… Hemostatic Diso… Clotting Disord… Transgenderism | per MCW IRB - | |||
| NCT04586920 2020-003957-30 Details | 2022-12-21 Interventional | 1 | 104 | Itraconazole Midazolam Healthy | Terminated due to safety findings - |